UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/817,950	03/27/2001	Paul M. Guyre	DC-0153	4097

26259 7590 03/24/2003

LICATLA & TYRRELL P.C.
66 E. MAIN STREET
MARLTON, NJ 08053

EXAMINER
BELYAVSKYI, MICHAIL A

ART UNIT	PAPER NUMBER
1644	

DATE MAILED: 03/24/2003

13

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/817,950	GUYRE ET AL.	
	Examiner	Art Unit	
	Michail A Belyavskyi	1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *18 January 2002* .

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-3* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1-3* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11)☐ The proposed drawing correction filed on _____ is: a)☐ approved b)☐ disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12)☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____ .

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14)☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) ☐ The translation of the foreign language provisional application has been received.

15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ .
4) ☐ Interview Summary (PTO-413) Paper No(s). _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: .

DETAILED ACTION

1. Applicant's amendment, filed 1/18/02 (Paper No. 12), is acknowledged.

Claims 1-3 are pending.

Claims 1-3 are under consideration in the instant application.

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/18/02 has been entered.

3. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention *to which the claims are directed.*

4. Upon consideration of Applicant's arguments in conjunction with provided evidence demonstrating the commercial availability of MAC 2-158 and MAC2-48 antibodies at the reasonable price from Maine Biotechnology Services Inc. (Paper No.12, filed 1/18/02) the previous rejection under 35 U.S.C. 112, first paragraph has been withdrawn. It is noted however, that according to Maine Biotechnology Services Inc., said antibody can be used only for *in vitro* research . (See attached 'Terms and Conditions" from Maine Biotechnology Services Inc).

In view of the amendment filed 1/18/02 (Paper No. 12), the following rejection remains:

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

6. Claims 1-3 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Coligan et al. (Current Protocols in Immunology, Greene Publishing Associates and Wiley-Interscience, New York, 1991; pages 2.1.1-2.1.3, 2.1.9-2.1.11, and 2.1.17-2.1.22) in view of U.S. Patent 5,077,216, and Zwadlo et al (IDS Reference BA) for the same reasons set forth in the previous Office Actions, Paper Nos : 7 and 9, mailed on 02/215/02 and 8/13/02 .

Applicant's arguments filed 1/18/02 have been fully considered but they are not persuasive.

Applicant asserts that : (i) Zwadlo et al does not teach monitoring the course of an inflammatory condition by detecting CD163; (ii) Coligan et al. only teach general method for conducting ELISAs and the '216 patent discloses antibodies against p155 (MAC2-158 and MAC2-48) and fails to provide any teaching or suggestion of CD163 acting as an early signaling event in the inflammatory response and there is no suggestion to combine the references.

Contrary to Applicant's assertions, it is noted that Applicants have traversed the primary and the secondary references pointing to the differences between the claims and the disclosure in each reference. Applicant is respectfully reminded that the rejection is under 35 USC 103 and that unobviousness cannot be established by attacking the references individually when the rejection is based on the combination of the references. see In re Keller, 642 F.2d 4B, 208 USPQ 871, 882 (CCPA 1981) See MPEP 2145. This applicant has not done, but rather argues the references individually and not their combination. One cannot show non-obviousness by attacking references individually where the rejections are based on a combination of references. In re Young 403 F.2d 759, 150 USPQ 725 (CCPA 1968).

In addition, it is noted that it appears that applicant and the examiner differ on interpretation of both the claimed methods and the prior art. It is the Examiner's position that Zwaldo et al. teach a method of monitoring the course of an inflammatory condition/process comprising detecting RM3/1 antigen (.i.e. CD161 antigen) in biological sample. Zwaldo et al. teach that RM3/1 antigen was found to be expressed to varying degrees, depending on the stage of inflammation (see page 299 in particular). Further, in acute inflammatory sites RM3/1 positive macrophages are found in various amounts depending on the stage of inflammation (page 303 in particular).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to use the MAC2-158 or MAC2-48 antibodies as capture antibodies taught by the '216 patent and the antibodies taught by Zwaldo et al. as the detection antibody in the ELISA assay taught by Coligan et al. to have a method for monitoring the course of an inflammatory condition or inflammatory response in a patient by detecting the levels of CD163 in the biological sample as taught by Zwaldo.

One of ordinary skill in the art would have been motivated to use the antibodies taught by the '216 patent and Zwaldo et al. in the ELISA taught by Coligan et al. because to detect and monitor the presence of CD163 in a biological sample, such as human plasma, during an inflammatory condition/process, such as rheumatoid arthritis by detecting CD163 (i.e. RM3/1 antigen) as taught by Zwaldo et al.

One of ordinary skill in the art at the time the invention was made would have been motivated to do so, because detecting CD163 levels can be used to monitor an inflammatory response cascade in the patient, as taught by Zwaldo et al . CD163 levels in biological sample can be detected using the antibodies taught by the '216 patent and Zwaldo et al. in the ELISA taught by Coligan et al.

From the combined teaching of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

7. No claims are allowed.

8. This is a RCE of application No. 09/817950. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is (703) 308-4232. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Michail Belyavskyi, Ph.D.
Patent Examiner
Technology Center 1600
March 24, 2003

PHILLIP GAMBEL, PH.D
PRIMARY EXAMINER
TC 1600
3/24/03



MAINE BIOTECHNOLOGY SERVICES, INC

Don't Tailor Your M

Search MBS | Products | GO | Order Online | Info R

MBS Terms & Conditions

Maine Biotechnology Services, Inc.

Terms and Conditions

Orders:
On-line ordering is available for Maine Biotechnology Services customers with shipping locations in the orders must contain a purchase order number or credit card number and the name of the person who is pla

Overseas orders can be taken through **customer service**. Orders can otherwise be received by fax (207-7 800-925-9476 (US only)or 207-797-5454 extension 21), or mail. Orders may be confirmed, but should be Only". All orders must contain a purchase order number or credit card number and the name of the perso order.

Mail orders to:

Maine Biotechnology Services, Inc
1037R Forest Avenue
Portland, Maine USA 04103

Pricing:
All prices listed or quoted are in US dollars and do not include shipping or handling fees. Current prices 2002, and are subject to change without notice. All quoted prices are valid for 60 days from the date of the otherwise.

Payment Terms:
Terms of payment for North American customers are Net 30 Days from date of invoice, pending credit app terms may apply. A 1.5% late fee will be applied to all overdue accounts. Prepayment is required for o international money orders or wire transfers. Please contact our **sales department** for additional infor orders.

Documents:
It is the customer's responsibility to notify Maine Biotechnology Services of all necessary documents or customs clearance or other purposes.

Handling Charges:

- Custom Services
- Products
- About Us
- Technical Resources

Blue Ice	$16.50 per carton
Dry Ice	$26.50 per carton
Special Export	$35.00 per Shipment
International Documentation	$50.00 per Shipment

Shipping:
Maine Biotechnology Services reserves the right to ship orders via the best method which will insure product, minimize freight costs, and allow efficient order tracking. The shipment of hazardous items is Department of Transportation and the International Air Transport Association (IATA).

All shipping charges are to be prepaid or shipments sent freight collect, unless prior arrangements for in have been made, or Federal Express customer account information is on file.

United States: Overnight shipment by Federal Express is available to applicable locations depending upon Overnight shipments to US locations are sent Monday-Thursday.

Canada: Overnight shipments to Canada are sent Monday-Friday. Duties and taxes are due on a collect bas

All other countries: Shipments overseas are sent Monday - Friday. Please inquire for shipping charges quot

Special Orders:
All shipment requiring dry ice will be subject to an additional fee. Please inquire.

Conditions of Sale:
All products contained in our catalog are for Investigational Use or for *In Vitro* Research Use Only. Prod use in research or manufacturing unless labeled for *In Vitro* Diagnostic Use. No products contained in th construed as a recommendation for use in violation of any patents. The responsibility for any patent dete with the user. Maine Biotechnology Services, Inc., is not responsible for any violations that may occur w products.

Return Policy:
No returns can be accepted without prior approval by Maine Biotechnology Services, Inc. Only unopened appropriate storage conditions may be returned. Maine Biotechnology Services must be notified within 1(shipping costs and a 25% handling fee will be paid by the customer. Product must be received by I Services, Inc. within 10 days after return has been authorized. In certain cases such as a return of dated m involving special handling, an additional fee may be required. No return of custom products will be authori specifications agreed upon prior to shipment.

Product Specifications
Data sheets and other product information for most Maine Biotechnology Services, Inc products can b additional product information please contact **technical support**.

Guidelines for Safe Use of the Products:
Maine Biotechnology Services recommends that the buyer and other persons using this product follow Gooc guidelines. Maine Biotechnology Services disclaims any and all responsibility for any injury or damage whic the failure of the buyer or any other person to follow said guidelines. It is the user's responsibility to deter any material and/or procedure for a specific purpose and to adopt such safety precautions as may be neces

Limited Warranty:
Maine Biotechnology Services, Inc warrants, to the original purchaser only, that the products listed in th composition and purity described therein. Buyer's exclusive remedy under this warranty is expressly limit unused product with product meeting the catalog description. Statements made about these products by Services, Inc sales persons or Maine Biotechnology Services, Inc distributors do not constitute warrantie relied upon by buyer. *The entire risk as to the performance of any product is assumed by buyer*. Maine Bio Inc shall not be liable for indirect, special or consequential damages resulting from use of the product. T warranties relating to the product, including any implied warranties or merchantability or of fitness for a pa or other purposes, are disclaimed.